Back to mobile site

Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 4c, Boosts Guidance

February 5, 2013 4:31 PM EST Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.42, $0.04 better than the analyst estimate of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login